O	0	1	A
O	2	12	randomised
O	13	18	pilot
O	19	24	Phase
O	25	27	II
O	28	33	study
O	34	36	of
B-intervention	37	48	doxorubicin
I-intervention	49	52	and
I-intervention	53	69	cyclophosphamide
I-intervention	70	71	(
I-intervention	71	73	AC
I-intervention	73	74	)
I-intervention	75	77	or
I-intervention	78	88	epirubicin
I-intervention	89	92	and
I-intervention	93	109	cyclophosphamide
I-intervention	110	111	(
I-intervention	111	113	EC
I-intervention	113	114	)
I-intervention	115	120	given
I-intervention	121	122	2
I-intervention	123	129	weekly
I-intervention	130	134	with
I-intervention	135	148	pegfilgrastim
I-intervention	149	150	(
I-intervention	150	161	accelerated
I-intervention	161	162	)
O	163	165	vs
O	166	167	3
O	168	174	weekly
O	175	176	(
B-control	176	184	standard
O	184	185	)
O	186	189	for
B-eligibility	190	195	women
I-eligibility	196	200	with
I-eligibility	201	206	early
I-eligibility	207	213	breast
I-eligibility	214	220	cancer
O	220	221	.

O	222	233	Accelerated
O	234	235	(
O	235	239	dose
O	239	240	-
O	240	245	dense
O	245	246	)
O	247	259	chemotherapy
O	259	260	,
O	261	263	in
O	264	269	which
O	270	273	the
O	274	283	frequency
O	284	286	of
O	287	301	administration
O	302	304	is
O	305	314	increased
O	315	322	without
O	323	331	changing
O	332	337	total
O	338	342	dose
O	343	345	or
O	346	354	duration
O	354	355	,
O	356	359	may
O	360	368	increase
O	369	372	the
O	373	381	efficacy
O	382	384	of
O	385	391	cancer
O	392	404	chemotherapy
O	404	405	.

O	406	408	We
O	409	418	performed
O	419	420	a
O	421	431	randomised
O	432	437	Phase
O	438	440	II
O	441	446	study
O	447	449	to
O	450	456	assess
O	457	460	the
O	461	467	safety
O	468	471	and
O	472	480	relative
O	481	489	toxicity
O	490	492	of
O	493	495	AC
O	496	497	(
O	497	508	doxorubicin
O	508	509	;
O	510	526	cyclophosphamide
O	526	527	)
O	528	530	vs
O	531	532	E
O	532	533	(
O	533	543	epirubicin
O	543	544	)
O	544	545	C
O	546	551	given
O	552	554	by
O	555	567	conventional
O	568	570	or
O	571	582	accelerated
O	583	592	schedules
O	593	595	as
O	596	607	neoadjuvant
O	608	610	or
O	611	619	adjuvant
O	620	632	chemotherapy
O	633	636	for
O	637	642	early
O	643	649	breast
O	650	656	cancer
O	656	657	.

O	658	669	Furthermore
O	669	670	,
O	671	674	the
O	675	683	relative
O	684	692	toxicity
O	693	695	of
O	696	707	doxorubicin
O	708	711	and
O	712	722	epirubicin
O	723	730	remains
O	731	740	uncertain
O	740	741	.

O	742	750	Patients
O	751	755	were
O	756	766	randomised
O	767	769	to
O	770	773	one
O	774	776	of
O	777	781	four
O	782	786	arms
O	786	787	;
O	788	792	four
O	793	800	courses
O	801	803	of
O	804	812	standard
O	813	814	3
O	815	821	weekly
O	822	838	cyclophosphamide
O	839	842	600
O	843	845	mg
O	846	847	m
O	847	848	(
O	848	849	-
O	849	850	2
O	850	851	)
O	852	854	in
O	855	866	combination
O	867	871	with
O	872	883	doxorubicin
O	884	886	60
O	887	889	mg
O	890	891	m
O	891	892	(
O	892	893	-
O	893	894	2
O	894	895	)
O	896	897	(
O	897	899	AC
O	899	900	)
O	901	903	vs
O	904	914	epirubicin
O	915	917	90
O	918	920	mg
O	921	922	m
O	922	923	(
O	923	924	-
O	924	925	2
O	925	926	)
O	927	928	(
O	928	930	EC
O	930	931	)
O	932	933	3
O	934	940	weekly
O	941	943	vs
O	944	947	the
O	948	952	same
O	953	961	regimens
O	962	974	administered
O	975	980	every
O	981	982	2
O	983	988	weeks
O	989	993	with
O	994	1007	pegfilgrastim
O	1008	1009	(
O	1009	1010	G
O	1010	1011	-
O	1011	1014	CSF
O	1014	1015	)
O	1015	1016	.

O	1017	1018	A
O	1019	1024	total
O	1025	1027	of
B-total-participants	1028	1031	126
O	1032	1040	patients
O	1041	1045	were
O	1046	1053	treated
O	1053	1054	,
B-control-participants	1055	1057	42
O	1058	1062	with
O	1063	1071	standard
O	1072	1074	AC
O	1074	1075	,
B-intervention-participants	1076	1078	42
O	1079	1083	with
O	1084	1095	accelerated
O	1096	1098	AC
O	1098	1099	,
B-intervention-participants	1100	1102	19
O	1103	1107	with
O	1108	1116	standard
O	1117	1119	EC
O	1120	1123	and
B-intervention-participants	1124	1126	23
O	1127	1131	with
O	1132	1143	accelerated
O	1144	1146	EC
O	1146	1147	.

O	1148	1161	Significantly
O	1162	1166	more
B-outcome	1167	1172	grade
I-outcome	1173	1174	3
I-outcome	1174	1175	/
I-outcome	1175	1176	4
I-outcome	1177	1180	day
I-outcome	1181	1184	one
I-outcome	1185	1196	neutropenia
O	1197	1200	was
O	1201	1205	seen
O	1206	1210	with
O	1211	1219	standard
O	1220	1221	(
B-cv-bin-abs	1221	1222	6
O	1222	1223	/
B-control-participants	1223	1225	61
O	1225	1226	,
B-cv-bin-percent	1227	1229	10
I-cv-bin-percent	1229	1230	%
O	1230	1231	)
O	1232	1240	compared
O	1241	1243	to
O	1244	1255	accelerated
O	1256	1257	(
B-iv-bin-abs	1257	1258	0
O	1258	1259	/
B-intervention-participants	1259	1261	65
O	1261	1262	,
O	1262	1263	)
O	1264	1272	regimens
O	1273	1274	(
O	1274	1275	P
O	1275	1276	=
O	1276	1277	0
O	1277	1278	.
O	1278	1280	01
O	1280	1281	)
O	1281	1282	.

O	1283	1284	A
O	1285	1290	trend
O	1291	1298	towards
O	1299	1303	more
B-outcome	1304	1315	neutropenic
I-outcome	1316	1322	sepsis
O	1323	1326	was
O	1327	1331	seen
O	1332	1334	in
O	1335	1338	the
O	1339	1347	combined
O	1348	1356	standard
O	1357	1360	and
O	1361	1372	accelerated
O	1373	1375	AC
O	1376	1380	arms
O	1381	1382	(
B-iv-bin-abs	1382	1384	12
O	1384	1385	/
B-intervention-participants	1385	1387	84
O	1387	1388	,
B-iv-bin-percent	1389	1391	14
I-iv-bin-percent	1391	1392	%
O	1392	1393	)
O	1394	1402	compared
O	1403	1405	to
O	1406	1409	the
O	1410	1418	combined
O	1419	1421	EC
O	1422	1426	arms
O	1427	1428	(
B-iv-bin-abs	1428	1429	1
O	1429	1430	/
B-intervention-participants	1430	1432	42
O	1432	1433	,
B-iv-bin-percent	1434	1435	2
I-iv-bin-percent	1435	1436	%
O	1436	1437	)
O	1437	1438	,
O	1439	1440	P
O	1440	1441	=
O	1441	1442	0
O	1442	1443	.
O	1443	1445	06
O	1445	1446	.

O	1447	1452	Falls
O	1453	1455	in
B-outcome	1456	1460	left
I-outcome	1461	1472	ventricular
I-outcome	1473	1481	ejection
I-outcome	1482	1490	fraction
O	1491	1495	were
O	1496	1499	not
O	1500	1509	increased
O	1510	1514	with
O	1515	1526	accelerated
O	1527	1536	treatment
O	1536	1537	.

O	1538	1549	Accelerated
O	1550	1552	AC
O	1553	1556	and
O	1557	1559	EC
O	1560	1564	with
O	1565	1578	pegfilgrastim
O	1579	1582	are
O	1583	1587	safe
O	1588	1591	and
O	1592	1600	feasible
O	1601	1609	regimens
O	1610	1612	in
O	1613	1616	the
O	1617	1626	treatment
O	1627	1629	of
O	1630	1635	early
O	1636	1642	breast
O	1643	1649	cancer
O	1650	1654	with
O	1655	1659	less
O	1660	1671	neutropenia
O	1672	1676	than
O	1677	1689	conventional
O	1690	1691	3
O	1692	1698	weekly
O	1699	1708	schedules
O	1708	1709	.
